CGRP Levels Are Over Twice as High in Rheumatoid Arthritis Patients and Correlate with Disease Activity
Serum CGRP levels were significantly elevated in RA patients (91.1 vs 40.8 pg/mL) and correlated with disease activity scores, suggesting CGRP as both a biomarker and potential therapeutic target.
Quick Facts
What This Study Found
Serum CGRP was significantly elevated in RA (91.1 vs 40.8 pg/mL, p<0.001), with seropositive patients showing higher levels (118.7 pg/mL). CGRP correlated with DAS-28, HAQ, and VAS scores and was an independent predictor of active disease.
Key Numbers
How They Did This
Cross-sectional case-control study with 80 RA patients and 40 healthy controls, using ELISA for CGRP measurement, ROC analysis for diagnostic cutoffs, and logistic regression for predictor analysis.
Why This Research Matters
CGRP is already targeted by migraine drugs (anti-CGRP antibodies). Finding it elevated in RA opens the question of whether these same drugs could help manage rheumatoid arthritis pain and inflammation.
The Bigger Picture
If CGRP contributes to RA pathophysiology (not just pain), anti-CGRP therapies already on the market for migraines could potentially be repurposed for RA, representing a new therapeutic avenue.
What This Study Doesn't Tell Us
Cross-sectional design cannot establish causation. Moderate sample size. Cannot determine if elevated CGRP drives disease or results from it. Single-center study.
Questions This Raises
- ?Could anti-CGRP antibodies (erenumab, fremanezumab) reduce RA disease activity?
- ?Does CGRP elevation precede RA flares and serve as an early warning biomarker?
- ?Is CGRP driving joint inflammation or primarily mediating RA-associated pain?
Trust & Context
- Key Stat:
- 91.1 vs 40.8 pg/mL RA patients had over twice the serum CGRP levels of healthy controls, with even higher levels in seropositive disease
- Evidence Grade:
- Well-designed case-control study with appropriate statistical analysis. Moderate sample size with clear findings, but cross-sectional design limits causal inference.
- Study Age:
- Published in 2026, representing emerging research on CGRP's role beyond migraine.
- Original Title:
- A Cross-Sectional Study on Elevated Serum Calcitonin Gene-Related Peptide Levels in Rheumatoid Arthritis Patients and Their Relationship with Disease Activity.
- Published In:
- Archives of rheumatology, 41(1), 29-39 (2026)
- Authors:
- Dede Akpınar, Merve, Ataoğlu, Safinaz, Cangür, Şengül
- Database ID:
- RPEP-15093
Evidence Hierarchy
Frequently Asked Questions
What is CGRP and why does it matter in arthritis?
CGRP (calcitonin gene-related peptide) is a neuropeptide involved in pain and inflammation. This study found it is significantly elevated in rheumatoid arthritis and correlates with how active the disease is, suggesting it plays a role in RA.
Could migraine drugs help with rheumatoid arthritis?
It is an interesting possibility. Anti-CGRP drugs used for migraines target the same molecule found elevated in RA. However, clinical trials would be needed to test whether they actually help with arthritis.
Read More on RethinkPeptides
Related articles coming soon.
Cite This Study
https://rethinkpeptides.com/research/RPEP-15093APA
Dede Akpınar, Merve; Ataoğlu, Safinaz; Cangür, Şengül. (2026). A Cross-Sectional Study on Elevated Serum Calcitonin Gene-Related Peptide Levels in Rheumatoid Arthritis Patients and Their Relationship with Disease Activity.. Archives of rheumatology, 41(1), 29-39. https://doi.org/10.5152/ArchRheumatol.2026.10704
MLA
Dede Akpınar, Merve, et al. "A Cross-Sectional Study on Elevated Serum Calcitonin Gene-Related Peptide Levels in Rheumatoid Arthritis Patients and Their Relationship with Disease Activity.." Archives of rheumatology, 2026. https://doi.org/10.5152/ArchRheumatol.2026.10704
RethinkPeptides
RethinkPeptides Research Database. "A Cross-Sectional Study on Elevated Serum Calcitonin Gene-Re..." RPEP-15093. Retrieved from https://rethinkpeptides.com/research/dede-2026-a-crosssectional-study-on
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.